OncoMatch/Clinical Trials/NCT06692738
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
Is NCT06692738 recruiting? Yes, currently enrolling (Sep 2026). This Phase 3 trial studies multiple treatments for non-small cell lung cancer.
Treatment: Rilvegostomig · Pembrolizumab · Carboplatin · Paclitaxel · Nab-paclitaxel — The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-ligand 1 (PD-L1).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) expression (TC ≥ 1%)
Provision of acceptable tumor sample to confirm tumor PD-L1 expression TC ≥ 1%
Disease stage
Required: Stage IIIB, IIIC, IV (other)
Stage III B/C or IV mNSCLC (based on the American Joint Committee on Cancer Edition 8) not amenable to curative treatment
Prior therapy
Cannot have received: anti-PD-1 therapy
Any prior treatment with an anti-PD-1 or anti-PD-L1 agent
Cannot have received: anti-PD-L1 therapy
Any prior treatment with an anti-PD-1 or anti-PD-L1 agent
Cannot have received: anti-TIGIT therapy
Any prior exposure to an anti-TIGIT therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms
Cannot have received: anticancer therapy targeting immune-regulatory receptors or mechanisms
Any prior exposure to an anti-TIGIT therapy or any other anticancer therapy targeting immune-regulatory receptors or mechanisms
Cannot have received: systemic, non-curative therapy for NSCLC
Any prior systemic, non-curative therapy received for NSCLC
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ and bone marrow function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Research Site · Tucson, Arizona
- Research Site · Springdale, Arkansas
- Research Site · Anaheim, California
- Research Site · Beverly Hills, California
- Research Site · Loma Linda, California
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06692738 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 expression is a required biomarker for enrollment.
What disease stage is eligible?
Stage IIIB or IIIC or IV is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify